Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 34 results for heavy menstrual bleeding

  1. Effectiveness of the progestogen-only pill, injectable progestogens, or progestogen implants in alleviating HMB:- How effective are the progestogen-only pill, injectable progestogens or progestogen implants in alleviating HMB?

    Source guidance details Comes from guidance Heavy menstrual bleeding: assessment and management Number NG88 Date issued

    Research recommendation
    Published
    14 November 2018

  2. Hysteroscopic removal of submucosal fibroids compared with other uterine-sparing treatments for HMB:- Is hysteroscopic removal of submucosal fibroids more effective and cost-effective than other uterine-sparing treatments for the management of HMB?

    Source guidance details Comes from guidance Heavy menstrual bleeding: assessment and management Number NG88 Date issued

    Research recommendation
    Published
    14 November 2018

  3. Long-term outcomes of pharmacological and uterine-sparing surgical treatments for HMB associated with adenomyosis:- What are the long-term clinical outcomes of pharmacological and uterine-sparing surgical treatments in women with HMB associated with adenomyosis?

    Source guidance details Comes from guidance Heavy menstrual bleeding: assessment and management Number NG88 Date issued

    Research recommendation
    Published
    14 November 2018

  4. Second-generation endometrial ablation for HMB associated with myometrial pathology:- Are outcomes after second-generation endometrial ablation for women with HMB associated with myometrial pathology (adenomyosis and/or uterine fibroids) equivalent to those for women without myometrial pathology?

    Source guidance details Comes from guidance Heavy menstrual bleeding: assessment and management Number NG88 Date issued

    Research recommendation
    Published
    14 November 2018

  5. Heavy menstrual bleeding: assessment and management (CG44)

    This guidance has been updated and replaced by NICE guideline NG88.

    Withdrawn guideline

  6. Endometriosis: diagnosis and management (NG73)

    This guideline covers diagnosing and managing endometriosis, including where fertility is a priority. It aims to raise awareness of endometriosis symptoms, and to provide clear advice on referral, diagnosis and the range of treatments available.

    NICE guideline
    Last updated
    11 November 2024
    View recommendations

    Sections for NG73

  7. Microwave endometrial ablation (IPG7)

    This guidance has been withdrawn as the use of this procedure is now covered in the NICE guideline on heavy menstrual bleeding (CG44). NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.

    Withdrawn guidance

  8. Free fluid thermal endometrial ablation (IPG51)

    Interventional procedures, IPG51 - Issued: March 2004 --> This guidance has been withdrawn as the use of this procedure is now covered in the NICE guideline on heavy menstrual bleeding: assessment and management. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme. 

    Withdrawn guidance

  9. Metreleptin for treating lipodystrophy (HST14)

    Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults.

    Highly specialised technologies guidance
    Published
    24 February 2021
    View recommendations

    Sections for HST14

  10. In addition to individual circumstances and needs, a woman's choice and acceptance of LARC may be influenced by potential health disbenefits (side effects and risks) as well as non‑contraceptive benefits of LARC (such as alleviation of menorrhagia). Large population studies of appropriate design are needed to determine the effect of these factors on the uptake of LARC methods and the implications for NHS resources.

    as well as non‑contraceptive benefits of LARC (such as alleviation of menorrhagia). Large population studies of appropriate design are...

    Research recommendation
    Published
    25 October 2019

  11. Menopause: identification and management (NG23)

    This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.

    NICE guideline
    Last updated
    7 November 2024
    View recommendations

    Sections for NG23

  12. Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids (HTG572)

    Evidence-based recommendations on transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids in adults. This involves inserting a device through the cervix into the womb to destroy the fibroid using radiofrequency energy.

    HealthTech guidance
    Published
    31 March 2021
    View recommendations

    Sections for HTG572

  13. Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids (HTG523)

    Evidence-based recommendations on ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids in adults. This involves focusing high-intensity ultrasound energy at the fibroids through the skin of the abdomen.

    HealthTech guidance
    Published
    24 July 2019
    View recommendations

    Sections for HTG523

  14. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

    Technology appraisal guidance
    Published
    16 April 2025

    Sections for TA1057

  15. Past appeals and decisions

    Past technology appraisal appeals and decisions